PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34429340-1	2021	BACKGROUND AND OBJECTIVE: To study whether dimethyl fumarate is superior to placebo in decreasing CSF concentrations of neurofilament light chain (NFL) in patients with primary progressive MS (PPMS).	Dimethyl Fumarate	43-60	neurofilament light chain	Homo sapiens	147-150	
31611264-7	2019	After 12 months of DMF treatment, NFL concentration decreased by 73%, 69% and 55% in the CSF, serum and plasma (p<0.0001, respectively).	Dimethyl Fumarate	19-22	neurofilament light chain	Homo sapiens	34-37